

StageZero Life Sciences teams up with resources giant Mercer to detect cancer early

As coronavirus is getting all the attention right now there is another disease that is far more deadly. It killed **9.6 million** people in 2017, and **every sixth death is because of this disease** globally. That disease is Cancer. The sad part is many of these deaths can be prevented if detected and treated early. This is why the world badly needs companies such as StageZero Life Sciences to succeed.

StageZero Life Sciences Ltd. (TSX: SZLS) is a Canadian company focused on developing and commercializing diagnostic tests for early detection of cancer. StageZero has developed the 'Sentinel Principle' platform technology which determines biomarkers from whole blood. StageZero's Aristotle® test is being well received as it is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Aristotle® platform has been validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer.

StageZero's Aristotle can test for 10 cancers from a single blood sample

1 Test - 10 Cancers - Unlimited Possibilities



Our next-generation test, Aristotle®, is a panel for simultaneously screening for 10 cancers from a single sample of blood. Aristotle has been built on our proprietary mRNA technology platform, which was validated in more than 10,000 patients for the development of the first liquid biopsy for Colorectal Cancer ([ColonSentry®](#)).

Colorectal, Prostate, Cervical, Endometrial, Breast, Ovarian, Liver, Bladder, Nasopharyngeal, and Stomach Cancer.

StageZero to join with global health and benefits marketplace leader Mercer to help screen for cancer

In recent news, StageZero announced: "StageZero Life Sciences to participate in Mercer's new vendor database in the U.S." The purpose is for Mercer Consultants to be able to do streamlined health and benefits vendor research on behalf of their clients in the U.S.

This is a big deal as Mercer is a world leader in the health and benefits marketplace, delivering innovative solutions that address the health and wellness needs of organizations and their employees. Mercer's clients include a majority of the companies in the Fortune 1000 and FTSE 100. Mercer is also reported to be the world's largest global asset manager with over US\$300 billion outsourced and US\$15 trillion under advisement in total. Mercer's more than 25,000 employees are based in 44 countries, and the firm operates in over 130 countries.

James Howard-Tripp, Chairman and CEO of StageZero, stated:

"The improved availability of our solution information to Mercer Consultants may help increase our exposure with employers in the U.S. We are very excited to be included in this valuable platform to connect with Mercer consultants."

Early stage cancer detection helps you become a cancer survivor



Closing thoughts

As the world focuses its attention on the coronavirus and billions of dollars are wiped from global markets, should we not ask why we are not using StageZero's 10 in 1 early cancer Aristotle® test. Mercer clearly thinks it is a good idea.

For investors with foresight, we should be able to envisage the day that everyone over 50 should undergo the Aristotle test. If that was to happen then StageZero would suddenly be overrun with orders and anyone who bought the stock now could be investment winners.

Certainly, the latest news of StageZero teaming up with one of the world's largest human resources companies may be the catalyst to get things moving. At the current market cap of just C\$9 million, the upside for StageZero Life Sciences could potentially be very rewarding.

StageZero's early cancer detection tests and telehealth platform are growing fast


Cancer is a terrible and common disease. According to the WHO: "One in 5 men and one in 6 women worldwide develop cancer during their lifetime; and one in 8 men and one in 11 women die from the disease." Experts all agree early detection is the key. I know from personal experience in my family that two lives have already been saved from detecting cancers early.

StageZero Life Sciences Ltd. (TSX: SZLS) is a Canada-based company focused on developing and commercializing molecular diagnostic tests for early detection of cancer. StageZero has developed the 'Sentinel Principle' platform technology which determines bio-markers from whole blood.

StageZero's diagnostic tests

Aristotle® is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Aristotle® platform has been validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer.

Chairman and CEO of StageZero Life Sciences, James Howard-Tripp, stated: "There is significant interest in being able to screen easily and routinely for multiple cancers, and our tests meet this need." Other StageZero diagnostic tests for early cancer detection include ColonSentry, BreastSentry, Prostate Health Index, and Early CDT-Lung.



**The Answers You Need...
Without the Wait.**

Order Your Test. Get Your Results. Know Your Risk.

StageZero expands partner agreement with Oncore Pharma

StageZero has now expanded its multi-year licensing agreement with Oncore Pharma Inc., a company that specializes in the research, development, and commercialization of oncology (cancer) products and services. In addition to the current agreement to commercialize ColonSentry® under an exclusive 5-year licensing agreement, Oncore Pharma will now add StageZero's BreastSentry and the Prostate Health Index to its portfolio of offerings. With two new products on offer through Oncore Pharma, test numbers should rise significantly. StageZero's diagnostic tests in Q3, 2019 were ~1,500.

Under the terms of the agreement, StageZero will receive a fee for processing and reporting of the tests and has received 1 million common shares of Oncore Pharma and will receive a special royalty payment equal to 10% of Oncore's yearly profits. Oncore Pharma's partner in the Benelux countries of Western Europe, BodyCheck NL, has indicated they will initiate

testing during the first quarter of 2020.

Martin Verronneau, the President and CEO of Oncore Pharma Inc., stated: “We created Oncore Pharma to focus specifically on research, development and commercialization of oncology products and ColonSentry is exactly the type of diagnostic test the market needs and our customers demand.”

StageZero expands its telehealth network

‘Telehealth’ allows long-distance patient and clinician contact, care, advice, reminders, education, intervention, monitoring, and remote admissions.

StageZero’s telehealth network can be used by patients to get the test ordered via a physician, then have their blood drawn at a nearby lab or in the comfort of their home, and then receive their test results online. Patients with elevated scores are encouraged to do a follow up with a telehealth physician online or over the phone to discuss results.



StageZero recently expanded its reach by signing new contracts with ARCPoint Labs and Phleb-Finders to build StageZero’s blood draw network to 500 locations and 10,000 mobile phlebotomists.

The telehealth program is beginning to show significant patient adoption as the program puts the patient in control by providing a convenient and private process for getting tested. The telehealth market is growing rapidly from a market of US\$49 billion in 2018 to a projected market of US\$266 billion by 2026, with 66% of Americans willing to use a telehealth platform.

How telehealth works for StageZero’s clients



Telehealth Model



StageZero also has its own laboratory. Their CAP-accredited and CLIA certified laboratory offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancer.

I am expecting big things from this company both as an investment and also as they are helping save lives by detecting cancer early. Q1 2020 should see a steady rise in diagnostic tests as the Oncore Pharma deal kicks in.